TY - JOUR
T1 - Melatonin and Parkinson Disease
T2 - Current Status and Future Perspectives for Molecular Mechanisms
AU - Tamtaji, Omid Reza
AU - Reiter, Russel J.
AU - Alipoor, Reza
AU - Dadgostar, Ehsan
AU - Kouchaki, Ebrahim
AU - Asemi, Zatollah
N1 - Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Parkinson disease (PD) is a chronic and neurodegenerative disease with motor and nonmotor symptoms. Multiple pathways are involved in the pathophysiology of PD, including apoptosis, autophagy, oxidative stress, inflammation, α-synuclein aggregation, and changes in the neurotransmitters. Preclinical and clinical studies have shown that melatonin supplementation is an appropriate therapy for PD. Administration of melatonin leads to inhibition of some pathways related to apoptosis, autophagy, oxidative stress, inflammation, α-synuclein aggregation, and dopamine loss in PD. In addition, melatonin improves some nonmotor symptom in patients with PD. Limited studies, however, have evaluated the role of melatonin on molecular mechanisms and clinical symptoms in PD. This review summarizes what is known regarding the impact of melatonin on PD in preclinical and clinical studies.
AB - Parkinson disease (PD) is a chronic and neurodegenerative disease with motor and nonmotor symptoms. Multiple pathways are involved in the pathophysiology of PD, including apoptosis, autophagy, oxidative stress, inflammation, α-synuclein aggregation, and changes in the neurotransmitters. Preclinical and clinical studies have shown that melatonin supplementation is an appropriate therapy for PD. Administration of melatonin leads to inhibition of some pathways related to apoptosis, autophagy, oxidative stress, inflammation, α-synuclein aggregation, and dopamine loss in PD. In addition, melatonin improves some nonmotor symptom in patients with PD. Limited studies, however, have evaluated the role of melatonin on molecular mechanisms and clinical symptoms in PD. This review summarizes what is known regarding the impact of melatonin on PD in preclinical and clinical studies.
KW - Apoptosis
KW - Autophagy
KW - Melatonin
KW - Oxidative stress
KW - Parkinson disease
UR - http://www.scopus.com/inward/record.url?scp=85070193292&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070193292&partnerID=8YFLogxK
U2 - 10.1007/s10571-019-00720-5
DO - 10.1007/s10571-019-00720-5
M3 - Review article
C2 - 31388798
AN - SCOPUS:85070193292
SN - 0272-4340
VL - 40
SP - 15
EP - 23
JO - Cellular and Molecular Neurobiology
JF - Cellular and Molecular Neurobiology
IS - 1
ER -